All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
Did you miss ASH 2019? The Multiple Myeloma Hub attended the 61st ASH Annual Meeting & Exposition, December 7-10 2019, Orlando, US, and has developed a downloadable resource on the practice-changing abstracts in multiple myeloma (MM).
In this resource, you will find comments from the MM Hub Steering Committee members on treating newly diagnosed patients with MM non-eligible for transplant, treating newly diagnosed patients with MM eligible for transplant, treating newly diagnosed patients with relapsed or refractory MM, autologous stem cell transplantation, treating patients with smoldering myeloma, CAR T-cell therapy and BiTEs, prognostic factors, and novel targets.
Updated November 25, 2020.
ASH 2019 | Practice-changing abstracts in multiple myeloma
If you would like to view the practice-changing abstracts from ASH 2019 and the expert opinions from our Steering Committee, please download the resource belowDownload Here
EHA 2019 | Highlights in newly diagnosed multiple myeloma
Mohamad Mohty from the Hôpital Saint-Antoine, Paris, FR, talks about the role of autologous stem cell transplant (ASCT) in the future treatment of multiple myeloma (MM).
ASH 2020| Practice-changing and breakthrough abstracts in multiple myeloma
The Multiple Myeloma Hub attended the virtual 62nd ASH Annual Meeting & Exposition, December, 5–8 2020, and has developed two downloadable resources, which provides...
Subscribe to get the best content related to multiple myeloma delivered to your inbox